First New York Securities’s Travere Therapeutics TVTX Stock Holding History

First New York Securities’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-83,000	Closed	-$974K	–	597
2014 Q2	$974K	Buy	+83,000	New	+$1.12M	1%	18

Other funds holding TVTX

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

LOAMU

Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

First New York Securities's TVTX Position: Q3 2014 in Review

First New York Securities sold out of Travere Therapeutics (TVTX) in Q3 2014, closing a stake of 83,000 shares — an estimated $974K sold.

First New York Securities first reported a position in TVTX in Q2 2014 and held it in 1 quarter. The position peaked at $974K in Q2 2014. 60 funds tracked by Wall St. Rank hold TVTX as of Q3 2014.

First New York Securities reported no remaining Travere Therapeutics position as of Q3 2014 after selling out during the quarter.
First New York Securities sold 83,000 Travere Therapeutics shares in Q3 2014, an estimated $974K.
First New York Securities first reported a position in Travere Therapeutics in Q2 2014 and held it in 1 quarter.
First New York Securities's Travere Therapeutics position peaked at $974K in Q2 2014.
60 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2014.

Based on First New York Securities's 13F filing for Q3 2014, filed 16 Oct 2014.